Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Macupatide (LY3532226) in Healthy Participants
NCT04923269Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), obesity and type 1 diabetes mellitus (T1D) comparing LY3532226 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started Jun 2021; status: completed.
02
Drugs
macupatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesitytype 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04923269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923269.